Log in to your Inderes Free account to see all free content on this page.
Herantis Pharma
2.54 EUR
-0.39 %
4,505 following
HRTIS
First North Finland
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-0.39 %
+24.51 %
+19.81 %
+10.43 %
+51.64 %
+59.25 %
+14.41 %
-34.70 %
-74.78 %
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Read moreMarket cap
61.2M EUR
Turnover
258.29K EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
5.3.
2026
Annual report '25
23.4.
2026
General meeting '26
20.8.
2026
Interim report Q2'26
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types
Herantis: Biomarker analysis completed successful Phase I
Herantis Pharma Plc, Phase 1b biomarker data webcast
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
